0000899243-19-016484.txt : 20190611 0000899243-19-016484.hdr.sgml : 20190611 20190611183830 ACCESSION NUMBER: 0000899243-19-016484 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190607 FILED AS OF DATE: 20190611 DATE AS OF CHANGE: 20190611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HALE DAVID F CENTRAL INDEX KEY: 0001024004 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 19892112 MAIL ADDRESS: STREET 1: 1042-B NORTH EL CAMINO REAL, SUITE 430 CITY: ENCINITAS STATE: CA ZIP: 92024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GTX INC /DE/ CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17 W PONTOTOC AVE. STREET 2: SUITE 100 CITY: MEMPHIS STATE: TN ZIP: 38103 BUSINESS PHONE: 901-523-9700 MAIL ADDRESS: STREET 1: 17 W PONTOTOC AVE. STREET 2: SUITE 100 CITY: MEMPHIS STATE: TN ZIP: 38103 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-07 0 0001260990 GTX INC /DE/ ONCT 0001024004 HALE DAVID F C/O ONCTERNAL THERAPEUTICS, INC. 12230 EL CAMINO REAL, SUITE 300 SAN DIEGO CA 92130 1 0 0 0 Common Stock 2019-06-07 4 A 0 699406 A 699406 I By Hale BioPharma Ventures, LLC. Common Stock 2019-06-07 4 A 0 18346 A 18346 I By Hale Trading Company. Warrants 6.13 2019-06-07 4 A 0 3292 A 2022-09-12 Common Stock 3292 3292 I By Hale BioPharma Ventures, LLC. Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. The warrants are currently exercisable. /s/ Hazel M. Aker, Attorney-in-fact 2019-06-11